HC Wainwright Reiterates "Buy" Rating for BioNTech (NASDAQ:BNTX)

Key Points

• HC Wainwright has reaffirmed a "buy" rating for BioNTech, setting a price target of $136.00, indicating a potential upside of 20.93% from the current stock price.
• BioNTech recently reported earnings of ($1.60) per share, missing estimates but achieving revenue of $306.46 million, which is significantly higher than expectations.
• The stock currently has an average rating of "Moderate Buy" from 17 analysts, with four recommending a hold, and a consensus price target of $135.80.

BioNTech (NASDAQ:BNTX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $136.00 price target on the stock. HC Wainwright's target price would suggest a potential upside of 40.58% from the stock's previous close.

A number of other equities analysts also recently issued reports on BNTX. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Truist Financial reaffirmed a "buy" rating and set a $155.00 price target (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. The Goldman Sachs Group started coverage on BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price target on the stock. Morgan Stanley upped their price target on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. Finally, Bank of America upped their price target on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Thirteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $135.80.

BioNTech Stock Down 7.3%

BioNTech stock traded down $7.57 during mid-day trading on Monday, reaching $96.74. 5,152,296 shares of the company were exchanged, compared to its average volume of 874,805. The business has a fifty day moving average of $108.79 and a 200 day moving average of $103.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The firm has a market cap of $23.26 billion, a P/E ratio of -60.46 and a beta of 1.39. BioNTech has a 12-month low of $81.20 and a 12-month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The company had revenue of $306.46 million for the quarter, compared to analysts' expectations of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The firm's quarterly revenue was up 102.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. Research analysts anticipate that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhenman & Partners Asset Management AB grew its position in BioNTech by 0.3% during the 2nd quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company's stock worth $3,819,000 after purchasing an additional 120 shares during the period. Kennedy Capital Management LLC grew its position in BioNTech by 0.8% during the 2nd quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company's stock worth $1,748,000 after purchasing an additional 127 shares during the period. Profund Advisors LLC grew its position in BioNTech by 3.6% during the 2nd quarter. Profund Advisors LLC now owns 4,309 shares of the company's stock worth $459,000 after purchasing an additional 149 shares during the period. Probity Advisors Inc. grew its position in BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after purchasing an additional 154 shares during the period. Finally, Banco Bilbao Vizcaya Argentaria S.A. grew its position in BioNTech by 2.5% during the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 7,653 shares of the company's stock worth $822,000 after purchasing an additional 186 shares during the period. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.